| [1] |
Praz F, Borger MA, Lanz J, et al. 2025 ESC/EACTS Guidelines for the management of valvular heart disease[J]. Eur Heart J, 2025 [2025-09-08].
URL
|
| [2] |
Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease[J]. Eur Heart J, 2022, 43(7):561-632.
|
| [3] |
中国医师协会心血管内科医师分会结构性心脏病专业委员会. 经导管主动脉瓣置换术中国专家共识(2020更新版)[J]. 中国介入心脏病学杂志, 2020, 28(6):301-309.
|
| [4] |
中国医师协会心血管内科医师分会结构性心脏病学组, 周达新, 吴永健, 等. 单纯主动脉瓣反流经股动脉主动脉瓣置换中国专家共识2023[J]. 中国介入心脏病学杂志, 2023, 31(11):801-809.
|
| [5] |
Egbe AC, Poterucha JT, Warnes CA. Mixed aortic valve disease: midterm outcome and predictors of adverse events[J]. Eur Heart J, 2016, 37(34):2671-2678.
|
| [6] |
Zilberszac R, Gabriel H, Schemper M, et al. Outcome of combined stenotic and regurgitant aortic valve disease[J]. J Am Coll Cardiol, 2013, 61(14):1489-1495.
|
| [7] |
Isaza N, Desai MY, Kapadia SR, et al. Long-term outcomes in patients with mixed aortic valve disease and preserved left ventricular ejection fraction[J]. J Am Heart Assoc, 2020, 9(7):e014591.
|
| [8] |
Lønborg J, Jabbari R, Sabbah M, et al. PCI in Patients undergoing transcatheter aortic-valve implantation[J]. N Engl J Med, 2024, 391(23):2189-2200.
|
| [9] |
Minten L, Wissels P, McCutcheon K, et al. The effect of coronary lesion complexity and preprocedural revascularization on 5-year outcomes after TAVR[J]. JACC Cardiovasc Interv, 2022, 15(16):1611-1620.
|
| [10] |
Dhoble A, Ahmed T, Mckay RG, et al. Timing and outcomes of PCI in conjunction with TAVR with balloon-expandable valves[J]. JACC Cardiovasc Interv, 2025, 18(2):244-254.
|
| [11] |
Stone GW, Abraham WT, Lindenfeld J, et al. Five-year follow-up after transcatheter repair of secondary mitral regurgitation[J]. N Engl J Med, 2023, 388(22):2037-2048.
|
| [12] |
Okuno T, Izumo M, Kuwata S, et al. Early-versus newer-generation transcatheter mitral valve edge-to-edge repair systems: insights from the OCEAN-Mitral registry[J]. JACC Asia, 2025, 5(9):1110-1120.
|
| [13] |
Anker SD, Friede T, von Bardeleben RS, et al. Transcatheter valve repair in heart failure with moderate to severe mitral regurgitation[J]. N Engl J Med, 2024, 391(19):1799-1809.
|
| [14] |
Sorajja P, Moat N, Badhwar V, et al. Initial feasibility study of a new transcatheter mitral prosthesis: the first 100 patients[J]. J Am Coll Cardiol, 2019, 73(11):1250-1260.
|
| [15] |
Kato N, Padang R, Scott CG, et al. The natural history of severe calcific mitral stenosis[J]. J Am Coll Cardiol, 2020, 75(24):3048-3057.
|
| [16] |
Okura H, Nakada Y, Nogi M, et al. Prevalence of mitral annular calcification and its association with mitral valvular disease[J]. Echocardiography, 2021, 38(11):1907-1912.
|
| [17] |
Churchill TW, Yucel E, Deferm S, et al. Mitral valve dysfunction in patients with annular calcification: JACC review topic of the week[J]. J Am Coll Cardiol, 2022, 80(7):739-751.
|
| [18] |
Chehab O, Roberts-Thomson R, Bivona A, et al. Management of patients with severe mitral annular calcification: JACC state-of-the-art review[J]. J Am Coll Cardiol, 2022, 80(7):722-738.
|
| [19] |
Eleid MF, Whisenant BK, Cabalka AK, et al. Early outcomes of percutaneous transvenous transseptal transcatheter valve implantation in failed bioprosthetic mitral valves, ring annuloplasty, and severe mitral annular calcification[J]. JACC Cardiovasc Interv, 2017, 10(19):1932-1942.
|
| [20] |
Bouleti C, Fassa AA, Himbert D, et al. Transfemoral implantation of transcatheter heart valves after deterioration of mitral bioprosthesis or previous ring annuloplasty[J]. JACC Cardiovasc Interv, 2015, 8(1 Pt A):83-91.
|
| [21] |
Sorajja P, Whisenant B, Hamid N, et al. Transcatheter repair for patients with tricuspid regurgitation[J]. N Engl J Med, 2023, 388(20):1833-1842.
|
| [22] |
Hahn RT, Makkar R, Thourani VH, et al. Transcatheter valve replacement in severe tricuspid regurgitation[J]. N Engl J Med, 2025, 392(2):115-126.
|
| [23] |
中国医师协会心血管内科医师分会结构性心脏病学组, 苏州工业园区东方华夏心管健康研究院. 三尖瓣反流经导管治疗的中国专家共识[J/OL]. 中华心脏与心律电子杂志, 2024, 12(3): 129-139.
|
| [24] |
Elbatarny M, Tam DY, Edelman JJ, et al. Valve-sparing root replacement versus composite valve grafting in aortic root dilation: a meta-analysis[J]. Ann Thorac Surg, 2020, 110(1):296-306.
|
| [25] |
Leontyev S, Schamberger L, Davierwala PM, et al. Early and late results after David vs Bentall procedure: a propensity matched aanalysis[J]. Ann Thorac Surg, 2020, 110(1):120-126.
|
| [26] |
Mastrobuoni S, de Kerchove L, Navarra E, et al. Long-term experience with valve-sparing reimplantation technique for the treatment of aortic aneurysm and aortic regurgitation[J]. J Thorac Cardiovasc Surg, 2019, 158(1):14-23.
|
| [27] |
Akowuah EF, Maier RH, Hancock HC, et al. Minithoracotomy vs conventional sternotomy for mitral valve repair: a randomized clinical trial[J]. JAMA, 2023, 329(22):1957-1966.
|
| [28] |
Thomas KL, Jackson LR, Shrader P, et al. Prevalence, characteristics, and outcomes of valvular heart disease in patients with atrial fibrillation: insights from the ORBIT-AF (Outcomes Registry for Better Informed Treatment for Atrial Fibrillation)[J]. J Am Heart Assoc, 2017, 6(12):e006475.
|
| [29] |
Whitlock RP, Belley-Cote EP, Paparella D, et al. Left atrial appendage occlusion during cardiac surgery to prevent stroke[J]. N Engl J Med, 2021, 384(22):2081-2091.
|
| [30] |
Gao Y, Luo H, Yang R, et al. Safety and efficacy of Cox-Maze procedure for atrial fibrillation during mitral valve surgery: a meta-analysis of randomized controlled trials[J]. J Cardiothorac Surg, 2024, 19(1):140.
|
| [31] |
Darehzereshki A, Mehaffey JH, Hayanga J, et al. Concomitant surgical ablation in paroxysmal vs persistent atrial fibrillation during mitral surgery[J]. Ann Thorac Surg, 2025, 119(2):389-397.
|
| [32] |
Kowalewski M, Dąbrowski EJ, Kurasz A, et al. Surgical ablation of atrial fibrillation with concomitant cardiac surgery: a state-of-the-art review[J]. Eur J Cardiothorac Surg, 2025, 67(7):ezaf187.
|
| [33] |
Van Mieghem NM, Unverdorben M, Hengstenberg C, et al. Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR[J]. N Engl J Med, 2021, 385(23):2150-2160.
|
| [34] |
Collet JP, Van Belle E, Thiele H, et al. Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial[J]. Eur Heart J, 2022, 43(29):2783-2797.
|